Pyridazinedione-based heterobicyclic covalent linkers and methods and applications thereof
US-2024425465-A1 · Dec 26, 2024 · US
Treatment of cancer with dihydropyrazino-pyrazines
US9630966B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9630966-B2 |
| Application number | US-201414254004-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 16, 2014 |
| Priority date | Apr 17, 2013 |
| Publication date | Apr 25, 2017 |
| Grant date | Apr 25, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are methods for treating or preventing glioblastoma multiforme (GBM) characterized by O6-methylguanine-DNA methyltransferase (MGMT) expression and/or promoter methylation status, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound to a patient having glioblastoma multiforme (GBM) characterized by O6-methylguanine-DNA methyltransferase (MGMT) expression and/or promoter methylation status.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating glioblastoma multiforme characterized by MGMT protein expression and/or promoter hypomethylation status, comprising administering an effective amount of 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof to a patient having glioblastoma multiforme characterized by MGMT protein expression or promoter hypomethylation status. 2. The method of claim 1 , wherein the glioblastoma multiforme is that in which the PI3K/mTOR pathway is activated. 3. The method of claim 2 , wherein the glioblastoma multiforme is that in which the PI3K/mTOR pathway is activated due to ERBB2 mutation, PTEN mutation or loss, NF1 mutation or loss, PIK3Ca mutation, EGFR mutation or overexpression, Met amplification, PDGFRa activation or amplification, AKT amplification, or a combination thereof. 4. The method of claim 1 , wherein said patient is administered about 0.5 mg/day to about 45 mg/day of 1ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof. 5. The method of claim 1 , wherein the glioblastoma multiforme is characterized by MGMT protein expression. 6. The method of claim 1 , wherein the glioblastoma multiforme is characterized by MGMT promoter hypomethylation.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antineoplastic agents · CPC title
Drugs for disorders of the nervous system · CPC title
- C07D487/04Primary
Ortho-condensed systems · CPC title
Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9630966B2 cover?
- Provided herein are methods for treating or preventing glioblastoma multiforme (GBM) characterized by O6-methylguanine-DNA methyltransferase (MGMT) expression and/or promoter methylation status, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound to a patient having glioblastoma multiforme (GBM) characterized by O6-methylguanine-DNA methyltransferase (MGMT) expre…
- Who is the assignee on this patent?
- Signal Pharm Llc
- What technology area does this patent fall under?
- Primary CPC classification C07D487/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 25 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).